High-throughput Drug Perturbation in Patient-Derived Gliomaspheres Enables Patient Stratification
- Value of deep genetic characterisation and functional genomics on low-passage patient-derived glioma tumorspheres
- Genetic biomarker identification and validation
- Rapid clinical impact of tumour precision targeting by clinical stage drugs